Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature
Authors' conclusion
Our findings suggest that JAK inhibitors may be a good therapeutic option, particularly in the management of refractory JDM cases with an acceptable safety profile.
Study context
- Population
- Juvenile dermatomyositis (JDM) patients treated with JAKi; median (min-max) age 4.9 (1–17) years (F/M:1.2)26 articles
- Participants
- 195 patients
- Comparison
- Tofacitinib vs Ruxolitinib vs Baricitinib
- Outcome
- Improvement rate by JAKi
Methodological detailsMEDLINE and Scopus, inception to September 1st, 2023
- MEDLINE and Scopus, inception to September 1st, 2023
Main finding
As reported in the abstract
Further findings
Indication for JAKi use
%
- Resistant/recurrent skin involvement
- 34.7
- Resistant/recurrent muscle involvement
- 28.6
Safety
- Patients with adverse events reported
- 72.1 %
- Most common: increase in infections (especially upper respiratory tract infections)
Original publication
Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature. Semin Arthritis Rheum. Published 1 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →